Drug Oncology

Padcev

Payments companies reported to CMS as associated with Padcev. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$4.7Massociated payments (2023-2025)

9,711clinicians with associated payments

8companies reporting

By year

2023 $1.5M

2024 $1.5M

2025 $1.7M

Payments reported as associated with Padcev, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Hematology & Oncology $2.2M

Medical Oncology $1.2M

Internal Medicine $362K

Urology $210K

Nurse Practitioner $146K

Family $120K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Padcev

These are the largest totals companies reported as associated with Padcev. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Peter O Donnell	Chicago, IL	Internal Medicine	$120,775.03
Carl Henningson	Manasquan, NJ	Hematology & Oncology	$113,705.47
Putao Cen	Houston, TX	Medical Oncology	$108,253.40
Przemyslaw Twardowski	Santa Monica, CA	Medical Oncology	$105,418.02
Daniel Milton	Indianapolis, IN	Hematology & Oncology	$99,817.57
Terence Friedlander	San Francisco, CA	Hematology & Oncology	$97,018.36
Amit Mehta	Cary, NC	Hematology & Oncology	$96,203.99
Nancy Dawson	Washington, DC	Medical Oncology	$90,279.67
Solly Chedid	Pascagoula, MS	Hematology & Oncology	$89,924.58
Daniel Landau	Orlando, FL	Hematology & Oncology	$84,378.93

Prescribed Padcev?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.